OXFORD, England--(BUSINESS WIRE)--Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch ® 3D genomics platform, today ...

Researchers at the University of East Anglia have helped develop a new blood test to detect prostate cancer with greater accuracy than current methods. New research shows that the Prostate Screening ...

The most common screening test for prostate cancer so often returns a false positive result that it's no longer recommended for men older than 70, and it's offered as a personal choice for younger men ...

For decades, the story of prostate cancer screening has been dominated by three letters: P-S-A. The Prostate-Specific Antigen blood test is the first line of defense for millions of men. Yet, for all ...

The accuracy of prostate-specific antigen (PSA) screening for prostate cancer can be improved by accounting for genetic factors that cause changes in PSA levels that are not associated with cancer, ...

There is both good news and bad news about prostate cancer screening. First, the bad news: the blood test involved, which measures a compound called prostate-specific antigen (PSA), is too inaccurate.

Medicare covers one annual prostate-specific antigen (PSA) test for people with prostates if they meet the eligibility guidelines and the test is medically necessary. Medicare typically covers one ...

A new blood test for prostate cancer that offers greater accuracy than prostate-specific antigen (PSA) has been put to the test by researchers at the University of East Anglia (UEA) in collaboration ...